IMIM - Institut Hospital del Mar d'Investigacions Mèdiques IMIM - Institut Hospital del Mar d'Investigacions Mèdiques

News

  • 2/12/2020 - Press release

    Hospital del Mar’s dual diagnosis care model is validated by experts from the UN and WHO

    The article published in the journal World Psychiatry and endorsed by the informal scientific network of the United Nations Office on Drugs and Crime (UNODC) and the World Health Organisation (WHO), and including the United States National Institute of Drug Abuse (NIDA), validates and corroborates the approach to the dual diagnosis implemented at Hospital del Mar for patients being treated for addiction to a substance of abuse who, in addition, suffer another psychiatric pathology. Dual diagnosis is a major health problem that causes, according to the article, an increased number of emergencies in healthcare centres, as well as more psychiatric hospitalisations, a higher risk of relapse into drug use and premature death, including suicide. This has individual and social repercussions, as well as consequences for healthcare systems, and means that a multidisciplinary and comprehensive approach is required. Nevertheless, as the authors of the paper point out, there is a generalised lack of preparedness to deal with this situation.

    Més informació "Hospital del Mar’s dual diagnosis care model is validated by experts from the UN and WHO"

  • 01/12/2020 - Press release

    Connecta Therapeutics, the CRG and the IMIM joint forces to develop an innovative treatment for fragile X syndrome

    The public-private consortium formed by the biotech company Connecta Therapeutics, the Centre for Genomic Regulation (CRG) and the Hospital del Mar Medical Research Institute (IMIM) has received a grant for 1,970,520 Euro from the Spanish National Innovation Agency to develop an innovative treatment for fragile X syndrome (FXS), the most common form of hereditary intellectual disability. The grant comes from the 2019 "Collaboration Challenges" call for projects of the National R&D&I Programme geared towards societal challenges. The call received 420 applications, 158 of which will be funded.

    Més informació "Connecta Therapeutics, the CRG and the IMIM joint forces to develop an innovative treatment for fragile X syndrome"

  • 27/11/2020 - Covid-19

    The importance of implementing a Transfusion Adjustment Programme in hospitals at the height of the COVID-19 epidemic

    The MAPBM (Maturity Assessment Model for Patient Blood Management) project is a useful tool that helps hospitals evaluate and develop their programmes for managing the blood of each patient (better known as PBM or patient blood management). This has been highlighted in an article published in the journal Blood Transfusion, led by doctors from Hospital del Mar and researchers from the Hospital del Mar Medical Research Institute (IMIM). PBM programmes are a set of therapeutic strategies, based on scientific evidence, aimed at improving the patient's condition prior to the surgical procedure, with particular focus on anaemia, minimising bleeding during surgery, and preventing or avoiding blood over-transfusion. They also have a direct impact by reducing the use of hospital blood reserves.

    Més informació "The importance of implementing a Transfusion Adjustment Programme in hospitals at the height of the COVID-19 epidemic"

  • 23/11/2020 - Institutional news

    The BAPP renews its TECNIO accreditation

    The BAPP (Bioanalysis, Proteomics and Pharmacology), a collaborative centre from the Hospital del Mar Medical Research Institute (IMIM) and the UPF, has obtained the TECNIO accreditation for the period 2020-2023.  This seal, which the centre had already obtained in previous editions, is awarded by the Government of Catalonia through ACCIÓN. It identifies and raises the profile of centres with high scientific and technical capacities that are considered to be developers of differential technologies and which are leaders when it comes to transferring their knowledge and technologies to industry. The BAPP is a multidisciplinary centre specialising in research and service activities in four sectors: pharmacology, neurosciences, peptide chemistry, and bioanalysis. Its main focus is the development of new drugs for human and veterinary use.  It comprises the Integrated Pharmacology and Systems Neuroscience (Farmacologia Integrada i Neurociència de Sistemes; FINS) research group of the IMIM-Hospital del Mar, on the one hand, and the Proteomics and Protein Chemistry research group from the UPF on the other.

    Més informació "The BAPP renews its TECNIO accreditation"

  • 12/11/2020 - Covid-19

    Comprehensive care model applied to prevent deterioration in older adults suffering COVID-19

    Offering comprehensive and multidisciplinary care to frail older patients admitted for COVID-19 makes it possible to reduce the impact hospitalisation and isolation have on their functional capacity. This has been demonstrated in a study by doctors and nurses at Hospital del Mar, which validates the usefulness of this comprehensive care model, ACE (Acute Care for Elders). The work has been published in the magazine Geriatric Nursing. The study followed 51 patients admitted during the first wave of COVID-19 to the Dr. Emili Mira Centre, a facility at the Mar Health Park that specialises in the care of psychiatric diseases and geriatric patients. The functional deterioration that appears in older adults during a hospital stay for acute illness (30-80% of geriatric patients admitted to hospital suffer a reduction in their capacities as a result of a hospital stay), is even more important in the case of COVID-19 because of the restrictions applied to the isolation units. To avoid this situation, a comprehensive care model, ACE, was implemented.

    Més informació "Comprehensive care model applied to prevent deterioration in older adults suffering COVID-19"

  • 10/11/2020 - General information

    The Spanish Society of Biological Psychiatry appoints Dr. Víctor Pérez as its President

    The director of the Neuropsychiatry and Addictions Institute at Hospital del Mar and coordinator of the Mental Health Research Group at the Hospital del Mar Medical Research Institute will be the president of the organisation for the next four years. Up to now, he has been the Vice-president of the society. Dr. Víctor Pérez, Director of the Institute of Neuropsychiatry and Addictions (INAD) at Hospital del Mar, will be the President of the Spanish Society of Biological Psychiatry (Sociedad Española de Psiquiatría Biológica; SEPB) for the next four years. He was elected at the society's Ordinary General Assembly, held virtually on 29 October.

    Més informació "The Spanish Society of Biological Psychiatry appoints Dr. Víctor Pérez as its President"

  • 05/11/2020 - General information

    The European Commission awards a six million euro grant to a project led by the Hospital del Mar Medical Research Institute

    The ICOD (Improving Cognition in Down Syndrome) project is being coordinated by the Integrated Pharmacology and Systems Neuroscience Research Group, led by Dr. Rafael de la Torre. It will trial a new therapy to treat cognitive deficits in Down Syndrome sufferers. Six institutions from Spain, France and Italy are taking part. A project led by the Hospital del Mar Medical Research Institute (IMIM), has received a six million euro development grant from the European Commission. The Improving Cognition in Down Syndrome (ICOD) project was one of 75 projects selected within the European Union's Horizon 2020 research and innovation programme. Only nine projects coordinated by Catalan organisations will benefit from these grants, in the last year they are being awarded.

    Més informació "The European Commission awards a six million euro grant to a project led by the Hospital del Mar Medical Research Institute"

  • 01/10/2020 - General information

    EU-funded Mental Health Promotion and Intervention in Occupational Settings

    Each year, around 20 million European citizens are affected from depression. Depression is a serious illness which impacts on all aspects of life, including work. While Small and Medium Sized enterprises particularly face substantial economic losses due to the global impact of COVID-19, the MENTUPP consortium anticipates, that capacities for mental health promotion and provision in Small and Medium Enterprises (SMEs) will be even more limited in the future. A second COVID-19 wave might further impact negatively on people affected by depression. This is why action on occupational mental health is urgently needed. Resources for Small and Medium Sized Enterprises "Limited capacities for mental health promotion and provision of adequate occupational mental health programmes for employees are a concern shared by most decision-makers in Small and Medium Sized Enterprises (SMEs)", says Prof. Ella Arensman, Coordinator of the MENTUPP project. In the EU, these businesses contribute to more than 90% of the economy. Particularly, SMEs in the construction, healthcare and Information and Communications Technology (ICT) sectors have been associated with higher risk of mental health difficulties compared to other sectors. COVID-19 has significant short-term and long-term effects on the mental health people working in these sectors. 

    Més informació "EU-funded Mental Health Promotion and Intervention in Occupational Settings"

  • 03/09/2020 - Press release

    European grant of 1.5 million euros to study how the brain encodes and stores our experiences

    The European Research Council (ERC) has awarded Dr. Arnau Busquets García, a Ramón y Cajal researcher at the Hospital del Mar Medical Research Institute (IMIM), with a prestigious ERC Starting Grant. This recognition includes 1.5 million euros to develop a 5-year project. Grants from the ERC, which are part of the European Union's Horizon 2020 research and innovation program, are the main source of European funding for research excellence. They support highly innovative projects led by outstanding and internationally renowned researchers, with the aim of helping them to build their own teams and carry out pioneering research in Europe. In this year's edition, 3272 applications were submitted and 436 grants were awarded, for a total of 677 million euros. The recipients have 40 different nationalities and the projects will be developed in 25 different EU member states. The countries awarded the most grants are Germany (88 grants), the UK (62), the Netherlands (42), and France (38). Spain secured a total of 23 grants, 7 of which are going to Catalan research centers.

    Més informació "European grant of 1.5 million euros to study how the brain encodes and stores our experiences"

  • 17/08/2020 - Press release

    Dr. Marta Torrens and Dr. Rafael Maldonado edit a special issue of European Neuropsychopharmacology on the recreational use of cannabis

    The journal is dedicating a prominent position to research on cannabis and its derivatives, its recreational use, the associated risks, and potential medical applications. It features articles by some of the most prominent figures in the field, under the editorship of Dr. Torrens and Dr. Maldonado. The July issue of the journal European Neuropsychopharmacology is dedicating a special section to the controversy over the globally growing trend to legalise the use of marijuana for certain recreational and medical uses. This has been edited by Dr. Marta Torrens, director of the Addictions Process Group at the Hospital del Mar Institute of Neuropsychiatry and Addictions (INAD) and coordinator of the Addictions Research Group at the Hospital del Mar Medical Research Institute (IMIM), and Dr. Rafael Maldonado, head of the Neuropharmacology Laboratory at the Department of Experimental and Health Sciences (CEXS) at Pompeu Fabra University and the IMIM. Together they authored an editorial on the subject for the journal.

    Més informació "Dr. Marta Torrens and Dr. Rafael Maldonado edit a special issue of European Neuropsychopharmacology on the recreational use of cannabis"

© Institut Hospital del Mar
d'Investigacions Mèdiques
Legal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact